83,780 Shares in Aurinia Pharmaceuticals Inc $AUPH Acquired by Navellier & Associates Inc.

Navellier & Associates Inc. acquired a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the third quarter, Holdings Channel reports. The fund acquired 83,780 shares of the biotechnology company’s stock, valued at approximately $926,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AUPH. State of Alaska Department of Revenue purchased a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth $91,000. USA Financial Formulas purchased a new stake in Aurinia Pharmaceuticals during the 3rd quarter valued at about $107,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at about $92,000. Bailard Inc. acquired a new stake in Aurinia Pharmaceuticals in the 2nd quarter valued at about $99,000. Finally, Union Bancaire Privee UBP SA purchased a new position in Aurinia Pharmaceuticals in the 3rd quarter worth approximately $136,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Upgrades and Downgrades

AUPH has been the topic of several recent research reports. Bloom Burton lowered Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $15.00 price objective (up previously from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Leerink Partners cut Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their target price for the company from $15.00 to $16.00 in a report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Jefferies Financial Group upgraded Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and lifted their price target for the stock from $10.00 to $21.00 in a report on Friday, November 7th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $17.25.

Aurinia Pharmaceuticals Stock Up 0.2%

AUPH stock opened at $14.56 on Wednesday. Aurinia Pharmaceuticals Inc has a one year low of $6.55 and a one year high of $16.54. The firm has a market cap of $1.92 billion, a PE ratio of 26.00 and a beta of 1.50. The firm’s 50 day moving average price is $15.31 and its 200-day moving average price is $13.60. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.17 and a current ratio of 5.76.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.